Cargando…

The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience

Detalles Bibliográficos
Autores principales:	Erhabor, Osaro, Ejele, OA, Nwauche, CA
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767052/ http://dx.doi.org/10.1186/1742-4690-6-S2-P66

Ejemplares similares

Absolute lymphocyte count as a marker for CD4 lymphocyte count: criterion for initiating antiretroviral therapy in HIV-infected Nigerians
por: Erhabor, Osaro, et al.
Publicado: (2009)

Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-Infected Ugandan Adults
por: Byakika-Tusiime, Jayne, et al.
Publicado: (2008)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)

Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm(3)
por: Manosuthi, Weerawat, et al.
Publicado: (2007)

Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Prior Co-administration of Rifampicin: A 144-week Prospective Study
por: Manosuthi, Weerawat, et al.
Publicado: (2008)

The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes
por: Gray, Lachlan R., et al.
Publicado: (2013)

Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults
por: Fehintola, Fatai A., et al.
Publicado: (2012)

Pharmacogenetic variation influences sensory neuropathy occurrence in Southern Africans treated with stavudine-containing antiretroviral therapy
por: Moketla, Marvin Blessings, et al.
Publicado: (2018)

Intrinsic Replication Competences of HIV Strains After Zidovudine/Lamivudine/Nevirapine Treatment in the Philippines
por: Kageyama, Seiji, et al.
Publicado: (2019)

Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort
por: Scarsi, Kimberly K., et al.
Publicado: (2016)

Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine versus Zidovudine-Lamivudine-Efavirenz Antiretroviral Treatment (ART) Among HIV-1 Infected Children: Asella Teaching and Referral Hospital, South-East Ethiopia
por: Sorsa, Abebe
Publicado: (2018)

Brain antioxidants and hippocampal microanatomical alterations following the administration of Efavirenz/Lamivudine/Tenofovir disoproxil fumarate and Lamivudine/Nevirapine/Zidovudine in adult male Wistar rats
por: Edagha, Innocent A., et al.
Publicado: (2022)

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort
por: Rokx, Casper, et al.
Publicado: (2014)

Incidence and Determinants of Nevirapine and Efavirenz-Related Skin Rashes in West Africans: Nevirapine's Epitaph?
por: Sarfo, Fred Stephen, et al.
Publicado: (2014)

Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA)
Publicado: (2008)

Relationship of ethnicity and CD4 Count with glucose metabolism among HIV patients on Highly-Active Antiretroviral Therapy (HAART)
por: Misra, Ranjita, et al.
Publicado: (2013)

Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing
por: Innes, Steve, et al.
Publicado: (2018)

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia
por: Llibre, Josep M., et al.
Publicado: (2015)

Post-dispensing stability surveillance: Stavudine
por: Naidoo, Kamsaladevi K., et al.
Publicado: (2009)

Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole
por: Manosuthi, Weerawat, et al.
Publicado: (2007)

Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans
por: Lukhwareni, Azwidowi, et al.
Publicado: (2020)

Toxicity Associated with Stavudine Dose Reduction from 40 to 30 mg in First-Line Antiretroviral Therapy
por: Pujades-Rodríguez, Mar, et al.
Publicado: (2011)

Incidence of Treatment-Limiting Toxicity with Stavudine-Based Antiretroviral Therapy in Cambodia: A Retrospective Cohort Study
por: Phan, Vichet, et al.
Publicado: (2012)

Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa
por: Maskew, Mhairi, et al.
Publicado: (2012)

Tolerability of antiretroviral therapy (HAART) in elderly age
por: Celesia, B M
Publicado: (2010)

Absolute lymphocyte count as a surrogate marker for CD4 counts after six months of HAART initiation in a resource-limited setting in India
por: Srirangaraj, S., et al.
Publicado: (2012)

Formulation and evaluation of floating matrix tablet of stavudine
por: Prajapati, Pankaj H, et al.
Publicado: (2012)

Heterogeneous responses of dorsal root ganglion neurons in neuropathies induced by peripheral nerve trauma and the antiretroviral drug stavudine
por: Boateng, EK, et al.
Publicado: (2015)

Trends in human papillomavirus (HPV) infection among HIV-positive women in the pre-HAART and HAART era in a Nigerian clinic
por: Onigbogi, MO, et al.
Publicado: (2010)

Effects of Switching from Stavudine to Raltegravir on Subcutaneous Adipose Tissue in HIV-Infected Patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A Clinical and Molecular Study
por: Domingo, Pere, et al.
Publicado: (2014)

Comparing Absolute Lymphocyte Count to Total Lymphocyte Count, as a CD4 T Cell Surrogate, to Initiate Antiretroviral Therapy
por: Sreenivasan, Srirangaraj, et al.
Publicado: (2011)

Environmental Risk Characterization of an Antiretroviral (ARV) Lamivudine in Ecosystems
por: Omotola, Elizabeth Oyinkansola, et al.
Publicado: (2021)

Adverse Events in a Cohort of HIV Infected Pregnant and Non-Pregnant Women Treated with Nevirapine versus Non-Nevirapine Antiretroviral Medication
por: Aaron, Erika, et al.
Publicado: (2010)

Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment
por: Shiau, Stephanie, et al.
Publicado: (2014)

Risk Factors of Treatment-Limiting Anemia after Substitution of Zidovudine for Stavudine in HIV-Infected Adult Patients on Antiretroviral Treatment
por: Phe, Thong, et al.
Publicado: (2013)

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China
por: Gu, Lijun, et al.
Publicado: (2015)

Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients
por: Podzamczer, Daniel, et al.
Publicado: (2014)

Formulation and Evaluation of Controlled Release Floating Microballoons of Stavudine
por: Vidyadhara, Suryadevara, et al.
Publicado: (2015)

HIV-positive Nigerian adults harbour significantly higher serum lumefantrine levels than HIV negative individuals seven days after treatment for Plasmodium falciparum infection
por: Chijioke-Nwauche, Ifevinwa, et al.
Publicado: (2012)

Trend of CD4+ Cell Counts at Diagnosis and Initiation of Highly Active Antiretroviral Therapy (HAART): Korea HIV/AIDS Cohort Study, 1992-2015
por: Kim, Min Jung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lgkug8qibdkomp7qtfi22q1uul